UBP-310
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522528

CAS#: 902464-46-4

Description: UBP-310 is a potent and selective GLUK5 kainate receptor antagonist (IC50 = 130 nM). UBP-310also blocks recombinant homomeric GLUK7 receptors.


Price and Availability

Size
Price

10mg
USD 280
Size
Price

Size
Price

UBP-310, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 522528
Name: UBP-310
CAS#: 902464-46-4
Chemical Formula: C14H15N3O6S
Exact Mass: 353.0682
Molecular Weight: 353.35
Elemental Analysis: C, 47.59; H, 4.28; N, 11.89; O, 27.17; S, 9.07


Synonym: UBP310, UBP 310, UBP-310

IUPAC/Chemical Name: (S)-3-((3-(2-amino-2-carboxyethyl)-5-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)thiophene-2-carboxylic acid

InChi Key: ZTAZUCRXCRXNSU-VIFPVBQESA-N

InChi Code: InChI=1S/C14H15N3O6S/c1-7-4-16(6-9(15)12(19)20)14(23)17(11(7)18)5-8-2-3-24-10(8)13(21)22/h2-4,9H,5-6,15H2,1H3,(H,19,20)(H,21,22)/t9-/m0/s1

SMILES Code: O=C1N(CC2=C(C(O)=O)SC=C2)C(C(C)=CN1C[C@H](N)C(O)=O)=O


Technical Data

Appearance:
White solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Buldyrev I, Puthussery T, Taylor WR. Synaptic pathways that shape the excitatory drive in an OFF retinal ganglion cell. J Neurophysiol. 2012 Apr;107(7):1795-807. doi: 10.1152/jn.00924.2011. Epub 2011 Dec 28. PubMed PMID: 22205648; PubMed Central PMCID: PMC3331668.

2: Atlason PT, Scholefield CL, Eaves RJ, Mayo-Martin MB, Jane DE, Molnár E. Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310. Mol Pharmacol. 2010 Dec;78(6):1036-45. doi: 10.1124/mol.110.067934. Epub 2010 Sep 13. PubMed PMID: 20837679; PubMed Central PMCID: PMC2993462.

3: Perrais D, Pinheiro PS, Jane DE, Mulle C. Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology. 2009 Jan;56(1):131-40. doi: 10.1016/j.neuropharm.2008.08.002. Epub 2008 Aug 12. PubMed PMID: 18761361.

4: Du M, Rambhadran A, Jayaraman V. Luminescence resonance energy transfer investigation of conformational changes in the ligand binding domain of a kainate receptor. J Biol Chem. 2008 Oct 3;283(40):27074-8. doi: 10.1074/jbc.M805040200. Epub 2008 Jul 24. PubMed PMID: 18658129; PubMed Central PMCID: PMC2556009.

5: Mayer ML, Ghosal A, Dolman NP, Jane DE. Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J Neurosci. 2006 Mar 15;26(11):2852-61. PubMed PMID: 16540562.